The Prevalence and Concurrent Pathogenic Mutations of KRASG12C in Northeast Chinese Non-small-cell Lung Cancer Patients

Clinical characteristics and prognostic value of the KRAS G12C mutation in Chinese non-small cell lung cancer patients

(2020) Si-Yang Liu et al.   Biomarker Research

Characteristics and Outcomes of Patients With Metastatic KRAS-Mutant Lung Adenocarcinomas: The Lung Cancer Mutation Consortium Experience

(2019) Badi El Osta et al.   Journal of Thoracic Oncology

K-ras Mutation Subtypes in NSCLC and Associated Co-occuring Mutations in Other Oncogenic Pathways

(2019) Matthias Scheffler et al.   Journal of Thoracic Oncology

KRASG12C inhibition produces a driver-limited state revealing collateral dependencies

(2019) Kevin Lou et al.   Science Signaling

Clinical features and therapeutic options in non‐small cell lung cancer patients with concomitant mutations of EGFR , ALK , ROS1 , KRAS or BRAF

(2019) Xibin Zhuang et al.   Cancer Medicine

Impact of KRAS mutation subtype and concurrent pathogenic mutations on non-small cell lung cancer outcomes

(2019) Jacqueline V. Aredo et al.   LUNG CANCER

Drugging K-RasG12C through covalent inhibitors: Mission possible?

(2019) Duan Ni et al.   PHARMACOLOGY & THERAPEUTICS

Discovery of a Covalent Inhibitor of KRASG12C (AMG 510) for the Treatment of Solid Tumors

(2019) Brian A. Lanman et al.   JOURNAL OF MEDICINAL CHEMISTRY

Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor

(2018) Matthew R. Janes et al.   CELL

STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS -Mutant Lung Adenocarcinoma

(2018) Ferdinandos Skoulidis et al.   Cancer Discovery

Characterization of distinct types of KRAS mutation and its impact on first‑line platinum‑based chemotherapy in Chinese patients with advanced non‑small cell lung cancer

(2017) Yijun Jia et al.   Oncology Letters

Cancer statistics in China, 2015

(2016) Wanqing Chen et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors

(2016) S. Ortiz-Cuaran et al.   CLINICAL CANCER RESEARCH

Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma

(2016) Zhong-Yi Dong et al.   CLINICAL CANCER RESEARCH

Differential association of STK11 and TP53 with KRAS mutation-associated gene expression, proliferation and immune surveillance in lung adenocarcinoma

(2015) M B Schabath et al.   ONCOGENE

Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy

(2015) W. Peng et al.   Cancer Discovery

Evidence that synthetic lethality underlies the mutual exclusivity of oncogenic KRAS and EGFR mutations in lung adenocarcinoma

(2015) Arun M Unni et al.   eLife

Targeting the KRAS variant for treatment of non-small cell lung cancer: potential therapeutic applications

(2015) Biagio Ricciuti et al.   Expert Review of Respiratory Medicine

The Prognostic Impact of KRAS, Its Codon and Amino Acid Specific Mutations, on Survival in Resected Stage I Lung Adenocarcinoma

(2014) Benjamin Izar et al.   Journal of Thoracic Oncology

KRAS-G12C Mutation Is Associated with Poor Outcome in Surgically Resected Lung Adenocarcinoma

(2014) Ernest Nadal et al.   Journal of Thoracic Oncology

Comprehensive molecular profiling of lung adenocarcinoma

(2014) Eric A. Collisson et al.   NATURE

ALK Rearrangements Are Mutually Exclusive with Mutations in EGFR or KRAS: An Analysis of 1,683 Patients with Non-Small Cell Lung Cancer

(2013) J. F. Gainor et al.   CLINICAL CANCER RESEARCH

Molecular Epidemiology of EGFR and KRAS Mutations in 3,026 Lung Adenocarcinomas: Higher Susceptibility of Women to Smoking-Related KRAS-Mutant Cancers

(2012) S. Dogan et al.   CLINICAL CANCER RESEARCH

New driver mutations in non-small-cell lung cancer

(2011) William Pao et al.   LANCET ONCOLOGY

Role ofKRASandEGFRAs Biomarkers of Response to Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21

(2008) Chang-Qi Zhu et al.   JOURNAL OF CLINICAL ONCOLOGY

Somatic mutations affect key pathways in lung adenocarcinoma

(2008) Li Ding et al.   NATURE